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Abstract
Introduction: Although a role of childhood body size in postmenopausal breast cancer risk has been established, less 
is known about its influence on tumour characteristics.
Methods: We studied the relationships between childhood body size and tumour characteristics in a Swedish 
population-based case-control study consisting of 2,818 breast cancer cases and 3,111 controls. Our classification of 
childhood body size was derived from a nine-level somatotype. Relative risks were estimated by odds ratios with 95% 
confidence intervals, derived from fitting unconditional logistic regression models. Association between somatotype at 
age 7 and tumour characteristics were evaluated in a case-only analysis where P values for heterogeneity were 
obtained by performing one degree of freedom trend tests.
Results: A large somatotype at age 7 was found to be associated with decreased postmenopausal breast cancer risk. 
Although strongly associated with other risk factors such as age of menarche, adult body mass index and 
mammographic density, somatotype at age 7 remained a significant protective factor (odds ratio (OR) comparing large 
to lean somatotype at age 7 = 0.73, 95% confidence interval (CI) = 0.58-0.91, P trend = 0.004) after adjustment. The 
significant protective effect was observed within all subgroups defined by estrogen receptor (ER) and progesterone 
receptor (PR) status, with a stronger effect for ER-negative (0.40, 95% CI = 0.21-0.75, P trend = 0.002), than for ER-
positive (0.80, 95% CI = 0.62-1.05, P trend = 0.062), tumours (P heterogeneity = 0.046). Somatotype at age 7 was not 
associated with tumour size, histology, grade or the presence or absence of metastatic nodes.
Conclusions: Greater body size at age 7 is associated with a decreased risk of postmenopausal breast cancer, and the 
associated protective effect is stronger for the ER-negative breast cancer subtype than for the ER-positive subtype.
Introduction
There is considerable evidence that childhood anthropo-
metric measurements are associated with postmeno-
pausal breast cancer risk. It has been consistently shown
that variables that approximate body shape and size early
in life are inversely associated with breast cancer risk in
adulthood. For example, a study conducted in 1998 on
the same data set as used in the current study [1]
reported that a larger somatotype at age seven years was
associated with a lower postmenopausal breast cancer
risk. Likewise, Hilakivi-Clarke and colleagues [2] found
that a shorter height and higher body mass in girls from
age 7 to 15 years were associated with a decreased inci-
dence of breast cancer. Berkey and colleagues [3] also
found extremely lean body mass at age 10 years to be
associated with elevated breast cancer risk. In another
study performed in 141,393 Danish girls, a high child-
hood body mass index (BMI) at age 14 years was shown
to be protective against breast cancer later on in life [4].
In addition, a study performed on the large Nurses'
Health Study dataset concluded that average body fatness
between the ages of 5 and 10 years are inversely associ-
ated with mammographic density [5], which is generally
considered to be an intermediate phenotype of breast
cancer [6].
Although a role of childhood body size in adult breast
cancer risk has been established, less is known about its
influence on tumour characteristics. One study by Bardia
and colleagues [7] looked into the risk of developing post-
menopausal breast cancer stratified by estrogen receptor
(ER) and progesterone receptor (PR) subtypes and
reported that an increase in weight at age 12 years was
* Correspondence: jingmei.li@ki.se
1 Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, 
Box 281, 171 77 Stockholm, Sweden
Full list of author information is available at the end of the articleBioMed Central
© 2010 Li et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attri-
bution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Li et al. Breast Cancer Research 2010, 12:R23
http://breast-cancer-research.com/2010/12/2/R23
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with the most pronounced effects exhibited by ER-posi-
tive/PR-negative tumours. No significant heterogeneity,
however, was observed between the tumour subtypes
studied. To our knowledge, no other study has been con-
ducted to assess whether pre-/peri-pubertal measure-
ments of body size can also influence tumour
characteristics. We thus followed up on the work of Bar-
dia and colleagues and in the present study examined the
relations between childhood body size to address if the
far-reaching effects of childhood body size have any
influence on tumour characteristics in adult cancers.
Materials and methods
Subjects
The subjects included in the current study are drawn
from a population-based case-control study of postmeno-
pausal breast cancer in Swedish-born women aged 50 to
74 years at the time of enrolment, which was between 1
October, 1993 and 31 March, 1995. Controls were ran-
domly selected from the Swedish registry and frequency
matched to the expected age distribution of the cases.
Details on data collection and subjects have been
described previously [1]. The final study group included
2,818 cases and 3,111 controls. Approval of the study was
given by the ethical review board at the Karolinska Insti-
tutet (Stockholm, Sweden) and six other ethical review
boards in the respective regions from which the subjects
were based.
Data collection and classification
With the exception of clinical data on tumour character-
istics and mammographic density, all other covariate data
were derived from the parent case-control study. Anthro-
pometric measurements at age seven years and one year
prior to enrolment were collected by means of a nine-
level somatotype (Figure 1) featured in the study ques-
tionnaire, and the validity of this measurement method
has been previously described [1]. These pictograms have
been validated against BMI within a cohort of 100 Cauca-
sian women from middle-class communities with an
average age of 73.1 years [8]. In a population-based vali-
dation study, 111 Swedish women aged 51 to 66 years
were found to have a correlation coefficient between BMI
from school records and adult report of somatotype at
age seven years of 0.6 [1]. The somatotypes were subse-
quently grouped as lean (S1 to S2), medium (S3 to S4) and
large (S5 to S9) prior to analysis. Other covariate data that
was collected using the self-reported study questionnaire
and examined in this study include age of menarche (con-
tinuous, in years), parity (continuous, number of live
births), history of benign breast disease (binary, never/
ever), BMI (continuous, in kg/m2), history of hormone
replacement therapy (HRT) (binary, never/ever), and
family history of breast cancer (binary, no/yes). Age at
menopause (continuous, in years) was also derived from
information collected in the study questionnaire and the
definition used in this study has been previously
described [1]. It is defined as the age at the last menstrual
period or the age at bilateral oophorectomy, if one year or
more prior to data collection. Women who have had a
hysterectomy, or who have not ceased menstruation due
to HRT, or with missing information on age at meno-
pause were considered to be postmenopausal if the age
reported at time of questionnaire was equal to or above
the 90th percentile of age at natural menopause of study
subjects (current smokers: 54 years old; nonsmokers: 55
years old, independent of case/control status). Subjects
classified as postmenopausal in this manner were
assigned an age at menopause according to their current
smoking status and the mean ages at natural menopause
in our data. Otherwise, women were considered to be
premenopausal and were excluded.
Information regarding the retrieval of tumour charac-
teristics from the medical records of all participants from
surgical and oncological units throughout Sweden have
been presented in detail elsewhere [9,10]. The tumour
characteristics in the present study included tumour size
(categorical, groups in cm), grade (categorical, classified
according to the Nottingham histological grade or
Bloom-Richardson scale), as well as ER and PR status
(binary, absent/present).
The process of collecting mammographic density data
in this study has been described previously [11]. Film
mammograms of the medio-lateral oblique view were
digitised using an Array 2905HD Laser Film Digitizer
(Array Corporation, Tokyo, Japan), which covers a range
of 0 to 4.7 optical density. For controls, breast side was
randomized. For cases, the side contralateral to the
tumour was used. The density resolution was set at 12-bit
spatial resolution. The Cumulus software used for the
computer-assisted thresholding was developed at the
University of Toronto [12]. For each image, a trained
observer (LE) set the appropriate gray-scale threshold
levels defining the edge of the breast and distinguishing
dense from non-dense tissue. The software calculated theFigure 1 Nine-level somatotype pictogram.
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and within the region identified as dense. These values
were used to calculate the percentage of the breast area
that is dense. A random 10% of the images were included
as replicates to assess the intra-observer reliability, which
was high with a Spearman rank correlation coefficient of
0.95. However, as not all women attended mammo-
graphic screenings, and some mammograms were miss-
ing, such information was available for only a subset of
the subjects (n = 3232, 54.5%).
Statistical analyses
The distribution of baseline characteristics of known
breast cancer risk factors were summarised as means and
standard deviations or proportions. Odds ratio (OR) esti-
mates with corresponding 95% confidence intervals (CI)
were computed by fitting unconditional logistic regres-
sion models with breast cancer risk status as the response
variable, adjusting for age.
To identify potential confounders of the association
between somatotype at age seven years and breast cancer
risk, linear/logistic regression models were fitted for
either continuous (age of menarche, age of menopause,
parity, BMI, and mammographic density) or binary
(benign breast disease and HRT) outcomes including
only controls in the analysis. Somatotype at age seven
years was treated as a categorical (three-level) indepen-
dent variable. Proportional odds logistic regression was
used in situations where the outcome variable was ordi-
nal (somatotypes at age seven years and one year prior to
enrolment) from which cumulative OR esimates with
corresponding 95% CIs were computed. Covariates were
considered potential confounders if there was a priori
evidence in the published literature of the factor being
associated with both childhood body size and breast can-
cer risk, or if the factor was significantly associated at the
5% level with both somatotype at age seven years and
breast cancer risk. Those covariates that, when added to
the model, changed the coefficient by more than 10%,
were considered confounders and adjusted for in the
multivariate analysis. The final variables in the multivari-
ate logistic regression model examining breast cancer risk
overall, and stratified by ER and PR tumour subtypes,
included age, age at menarche, benign breast disease, and
BMI one year prior to enrolment (recent BMI). Adjust-
ment for other variables did not influence the somatotype
risk estimates. Mammographic density was also identi-
fied as a confounder. However, as mammographic density
data are only available for a subset of the subjects, this
variable was accounted for together with the other risk
factors in a separate model. Women with and without
mammographic density information were not found to
differ significantly at the 5% level for the covariates
included in the analysis models (data not shown).
Associations between somatotype at age seven years
and tumour characteristics were evaluated in a case-only
analysis, by fitting ordinal regression models treating
tumour characteristics as dependent variables, with
somatotype at age seven years included as a covariate. P
values for heterogeneity were obtained by performing
one degree of freedom trend tests. As there exists prior
evidence that certain tumour characteristics such as ER
status are associated with age at diagnosis [13], and that
somatotype at age seven years is significantly associated
with age of diagnosis at the 5% level (regression coeffi-
cient for age in years of -0.91 with corresponding 95% CI
of -1.32 to -0.50), every model fitted in the case-only anal-
ysis was also adjusted for age at diagnosis. All analyses
were performed using the statistical software R for Win-
dows version 2.8.0 (R Development Core Team, Vienna,
Austria) [14]. The level of significance was set at 5%. All
statistical tests were two-sided.
Results
Table S1 in Additional file 1 describes the characteristics
of study subjects with respect to several breast cancer risk
factors. Age of menarche was weakly but positively asso-
ciated with the disease (OR per year increase in age of
menarche = 0.96, 95% CI = 0.93 to 1.00, P = 0.057), a
result consistent with the literature [4]. Family history,
age at menopause, parity, age of first birth, benign breast
disease, mammographic density, recent BMI and use of
HRT were strongly significant for breast cancer risk with
effects in a direction consistent with those estimated in
other epidemiological studies. The first association analy-
ses we performed between somatotypes at different ages
and breast cancer risk were adjusted for age at enrolment
only. Among the different measurements of somatotypes,
only the time point at age seven years was found to affect
breast cancer risk (OR per increase in somatotype class =
0.87, 95% CI = 0.8 to 0.95, P = 0.001). A larger proportion
of cases than controls had a leaner body shape at age
seven years. Despite somatotype one year prior to enrol-
ment having a high correlation to recent BMI (Spearman
correlation coefficient: 0.760, data not shown), it was not
found to be significantly associated with breast cancer
(OR per increase in somatotype class = 1.04, 95% CI =
0.94 to 1.15, P = 0.160).
To identify potential confounders of the association
between somatotype at age seven years and breast cancer
risk, we assessed whether other established risk factors
for breast cancer are associated with somatotype at age
seven years. An increase in childhood body size was
found to exhibit strong inverse associations with age of
menarche (OR comparing large to lean somatotype at age
seven years = 0.61, 95% CI = 0.50 to 0.76, P trend <
0.0001), benign breast disease (0.47, 95% CI = 0.25 to
0.89, P trend = 0.006), and mammographic density (0.61,
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Risk factor (dependent variable) Somatotype 
(independent variable)
n OR 95% CI P trend*
Age of menarche (years) Lean 1456 1.00 reference <0.0001
Medium 669 0.72 0.64 0.82
Large 187 0.61 0.50 0.76
Age of menopause (years) Lean 1572 1.00 reference 0.697
Medium 736 1.19 0.85 1.68
Large 204 0.93 0.53 1.65
Parity (Number of live births) Lean 1578 1.00 reference 0.217
Medium 745 0.93 0.83 1.05
Large 207 0.93 0.76 1.13
Benign breast disease Lean 1578 1.00 reference 0.006
Medium 745 0.76 0.56 1.03
Large 207 0.47 0.25 0.89
Somatotype one year prior to enrolment Lean 1571 1.00 reference <0.0001
Medium 739 1.72 1.44 2.05
Large 206 2.33 1.70 3.18
BMI (kg/m2) Lean 1562 1.00 reference <0.0001
Medium 742 1.85 1.30 2.65
Large 205 2.66 1.47 4.83
Percent mammographic density (%)† Lean 862 1.00 reference 0.001
Medium 428 0.72 0.58 0.91
Large 108 0.61 0.41 0.90
HRT Lean 1569 1.00 reference 0.868
Medium 739 0.99 0.83 1.18
Large 206 0.98 0.73 1.32
Other independent variables
Birthweight (g) on somatotype at age 7 ≤2500 49 1.00 reference 0.014
2500-3000 229 1.18 0.61 2.29
3000-3500 470 1.29 0.68 2.43
3500-4000 397 1.44 0.76 2.73
>4000 135 1.89 0.95 3.76
Family history on somatotype at age 7 No 2258 1.00 reference 0.485
Yes 227 1.10 0.84 1.44
* Based on Wald tests for regression coefficients in continuous, ordinal or logistic regression models (see statistical analyses section). All 
regression models were adjusted for age at enrolment. † Subset with phenotypic data. BMI, body mass index; CI, confidence interval; HRT, 
hormone replacement therapy; OR, odds ratio.
95% CI = 0.41 to 0.90, P trend = 0.001; Table 1). Associa-
tions in the opposite direction were found for proxy mea-
sures of physique at other time points, such as birth
weight (OR comparing birthweight >4000 g to ≤2500 g =
1.89, 95% CI = 0.95 to 3.76, P trend = 0.014), somatotype
one year prior to enrolment (OR comparing large to lean
somatotype at age seven years = 2.33, 95% CI = 1.70 to
3.18, P trend < 0.0001) and recent BMI (2.66, 95% CI =
1.47 to 4.83, P trend < 0.0001). No evidence of association
was found between age of menopause and somatotype at
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type at age seven years. Parity and HRT were found to be
independent of somatotype at age seven years (0.93, 95%
CI = 0.76 to 1.13, P trend = 0.217 and 0.98, 95% CI = 0.73
to 1.32, P trend = 0.868, respectively).
After adjustment of known breast cancer predictors
and other associated risk factors, the inverse association
of somatotype at age seven years with breast cancer
remained highly significant (Table 2; OR comparing large
to lean somatotype at age seven years = 0.73, 95% CI =
0.58 to 0.91, P trend = 0.004). The protective effect of a
larger somatotype was found to be significant (P trend <
0.05) for ER-negative, PR-positive and PR-negative sub-
types and marginally significant (P trend = 0.062) for the
ER-positive subtype. Within the group consisting of large
somatotypes, the most prominent effects were shown in
ER-negative (OR comparing large to lean somatotype at
age seven years = 0.40, 95% CI = 0.21 to 0.75, P trend =
0.002) and PR-negative (0.63, 95% CI = 0.40 to 0.99, P
trend = 0.028) tumours. The point estimates changed
very little before and after additional adjustment for
mammographic density as a continuous variable [see
Table S2 in Additional file 2], using a subset of the data
with this information available (n = 3232).
We next assessed the effects of childhood body size on
tumour characteristics (ER status, PR status, tumour size,
grade, histology, and absence/presence of metastatic
nodes) by fitting binary/ordinal logistic regression mod-
els, adjusting for age at diagnosis in years as a confounder.
We established that the protective effect of somatotype at
age seven years was significantly stronger for ER-negative
disease than for ER-positive disease (P heterogeneity =
0.046; Table 3). When comparing between two extreme
groups, women with a larger body size at age seven years
were 1.71 times (95% CI = 0.96 to 3.06) more likely to get
ER-positive than ER-negative disease after menopause.
Although the estimated trend suggests that women with
the same physique are more likely to get the PR-positive
disease in adulthood, the difference between the two
tumour subtypes was not significant (P heterogeneity =
0.283). The point estimates for tumour size, histology,
grade, or the presence or absence of metastatic nodes did
not vary much before and after adjustment for age of
diagnosis as a continuous variable.
Discussion
Our first main finding was that a large somatotype at age
seven years was associated with a decreased risk of post-
menopausal breast cancer. Although strongly associated
with other risk factors such as age of menarche, adult
BMI and mammographic density, somatotype at age
seven years remained a significant protective factor (OR
comparing large to lean somatotype at age seven years =
0.73, 95% CI = 0.58 to 0.91, P trend = 0.004) after adjust-
ment for these other risk factors. Our second and most
novel finding was of a significant protective effect of
somatotype at age seven years regardless of receptor sta-
tus, but with a stronger effect for ER-negative (0.40, 95%
CI = 0.21 to 0.75, P trend = 0.002), than for ER-positive
(0.80, 95% CI = 0.62 to 1.05, P trend = 0.062), tumours (P
heterogeneity = 0.046).
Our findings regarding the protective effects of child-
hood body size for adult breast cancer are consistent with
previous studies [3-5]. Associations with other breast
cancer risk factors were also in the same direction as
found in other epidemiological studies. Several studies
have found birth weight and gain in BMI in early child-
hood to predict adult lean mass, while adult adiposity has
been attributed to weight gain in late childhood and ado-
lescence [15-19]. Similarly, anthropometric measure-
ments at other time points (birth weight, and somatotype
one year prior to enrolment) in our data were found to be
positively associated with somatotype at age seven years.
The adverse effects of birth weight and adult body mass
on postmenopausal breast cancer risk may be explained
by a surplus of estrogen exposure from either the uterine
environment or excess adipose tissue [4,20]. However,
studies performed on children have not consistently
found an association between obesity and circulating
estradiol levels [21,22], thus it is unclear what mecha-
nisms drive the associated decrease in risk during the
pre-/peri-puberty window.
Strong inverse relationships found between childhood
body size, age of menarche, benign breast disease, and
mammographic density were in line with other reports in
the literature. Baer and colleagues [23] found a large
childhood body size to be associated with a decrease in
risk of benign breast disease. Age of menarche is often
considered along with age of menopause and other hor-
monal risk factors for a woman's cumulative exposure to
estrogen [24,25]. An earlier age of menarche is associated
with an increased risk of breast cancer. On the other
hand, a larger childhood somatotype, which is associated
with decreased breast cancer risk, is also associated with
an earlier age of menarche. As age of menarche is an
established but weak predictor of breast cancer risk, its
pronounced inverse relationship with childhood body
size when seen in the context of breast cancer risk seems
to be counterintuitive [26,27].
Mammographic density has also been found by others
to be associated with childhood body mass [5]. Estrogen
is produced by adipose tissue in the body. A higher BMI is
thus correlated with higher endogenous estrogen levels.
In a murine study, exposure to estrogen prior to puberty
led to a decrease in radiologically dense tissue and an
increase in the number of radiolucent structures [28],
which may be analogous to a lower mammographic den-
sity in humans. In agreement, McCormack and col-
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associated with a lower Wolfe grade, and Samimi and col-
leagues [5] found that a rounder pre-pubertal body shape
was predictive of lower mammographic density later in
life.
The age-adjusted case-only comparison of our data
reflected a significant difference in the effects of child-
hood body size on the two ER subtypes (P trend = 0.046),
but not the PR subtypes. However, in lieu of the fact that
PR is an estrogen-induced target gene, and that its pres-
ence could serve to indicate ER functional capacity and
tumour differentiation state [30], we also conducted
stratified analyses on PR subtypes. We found that the
protective trend conferred by a larger childhood somato-
type on postmenopausal breast cancer applies to all ER
and PR tumour subtypes. Overall our results were consis-
tent with Bardia and colleagues [7], although in that study
the effects were only significant for ER-positive (0.80,
95% CI = 0.67 to 0.96) and PR-negative (0.62, 95% CI =
0.43 to 0.89) tumours (comparing women with above
average weight at age 12 years to women with average
weight at age 12 years). Although Bardia and colleagues
observed a stronger protective effect in ER-negative
tumours than in their ER-positive counterparts (in agree-
ment with our finding) when comparing women with
above average weight at age 12 years to women with aver-
age weight at age 12 years, the association they observed
in this subgroup was not statistically significant (0.77,
95% CI = 0.5 to 1.19).
Hormonal exposure and mammographic density are
established risk factors of breast cancer that have been
suggested to be independent, operating through different
pathways [31]. Adjustment for these factors and other
traditional risk factors did not attenuate the negative
association of childhood body size on breast cancer risk
(OR comparing large to lean somatotype at age seven
years = 0.73, 95% CI = 0.58 to 0.91, P trend = 0.004, for
association, after adjustment), thus suggesting an inde-
pendent underlying mechanism. We speculate that a pos-
sible mechanism driving the negative association with
breast cancer risk could be epigenetic changes that occur
during mammary development. Hilakivi-Clarke [32]
summarised in a review several perspectives on special
windows of mammary development. Mammary tissue is
postulated to undergo epigenetic extensive modelling or
re-modelling during different stages in life such as fetal
development, puberty or pregnancy. Such epigenetic
modification can persist into adulthood if taken place in
mammary stem cells, uncommitted mammary myoepi-
thelial or luminal progenitor cells and inherited by subse-
Table 2: Multivariate-adjusted OR estimates and corresponding 95% CIs of postmenopausal breast cancer for somatotype 




Cases OR 95% CI P trend*
All data Lean 1784 1.00 reference 0.004
Medium 757 0.90 0.79 1.02
Large 173 0.73 0.58 0.91
ER positive Lean 963 1.00 reference 0.062
Medium 408 0.91 0.78 1.06
Large 98 0.80 0.62 1.05
ER negative Lean 219 1.00 reference 0.002
Medium 81 0.77 0.58 1.03
Large 14 0.40 0.21 0.75
PR positive Lean 841 1.00 reference 0.027
Medium 354 0.89 0.75 1.04
Large 83 0.76 0.57 1.00
PR negative Lean 320 1.00 reference 0.028
Medium 126 0.86 0.68 1.08
Large 25 0.63 0.40 0.99
* Logistic regression models were used, accounting for age, age at menarche, benign breast disease and recent body mass index. CI, 
confidence interval; ER, estrogen receptor; OR, odds ratio; PR, progesterone receptor.
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Table 3: Relation of somatotype at age seven years to tumour-defined characteristics of breast cancer
Tumour 
characteristics
Categories Somatotype at age seven years P heterogeneity§
S1-S2 S3-S4 S5-S9
Tumour size (cm)* <1 300 138 39
1-2 752 299 70
2-3 366 152 31
3-4 116 66 14
4-5 52 16 3
>=5 65 26 4
Cumulative OR (95% 
CI)
1.00 (ref.) 1.00 (0.85-1.17) 0.78 (0.58-1.05) 0.255
Cumulative OR (95% 
CI) §
1.00 (ref.) 1.00 (0.85-1.18) 0.78 (0.58-1.06) 0.266
Grade* Low 159 69 20
Medium 479 186 46
High 463 222 51
Cumulative OR (95% 
CI)
1.00 (ref.) 1.15 (0.94-1.41) 0.99 (0.69-1.43) 0.443
Cumulative OR (95% 
CI) §
1.00 (ref.) 1.15 (0.93-1.41) 0.99 (0.69-1.42) 0.463
Histology* Ductal 1350 570 137
Lobular 206 77 16
All other 92 37 7
Cumulative OR (95% 
CI)
1.00 (ref.) 0.91 (0.72-1.15) 0.76 (0.48-1.20) 0.192
Cumulative OR (95% 
CI) §
1.00 (ref.) 0.92 (0.73-1.17) 0.79 (0.50-1.25) 0.265
Metastatic nodes† Absent 1159 473 116
Present 513 227 46
OR (95% CI) 1.00 (ref.) 1.08 (0.90-1.31) 0.90 (0.63-1.28) 0.923
OR (95% CI) § 1.00 (ref.) 1.07 (0.88-1.29) 0.86 (0.60-1.23) 0.878
ER status† Negative 219 81 14
Positive 963 408 98
OR (95% CI) 1.00 (ref.) 1.15 (0.87-1.52) 1.59 (0.89-2.84) 0.089
OR (95% CI) § 1.00 (ref.) 1.18 (0.89-1.56) 1.71 (0.96-3.06) 0.046
PR status† Negative 320 126 25
Positive 841 354 83
OR (95% CI) 1.00 (ref.) 1.07 (0.84-1.36) 1.26 (0.79-2.01) 0.307
OR (95% CI) § 1.00 (ref.) 1.07 (0.84-1.37) 1.28 (0.80-2.03) 0.283
*Proportional odds logistic regression models were used. † Logistic regression models were used. ‡ Derived from one degree of freedom 
trend tests. § Adjusted for age at diagnosis. CI, confidence interval; ER, estrogen receptor; OR, odds ratio; PR, progesterone receptor.
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estrogen has been shown to upregulate the expression of
BRCA1, a well-known DNA repair gene [28]. Liu and col-
leagues [34] also demonstrated that BRCA1 is responsible
for differentiating ER-negative stem/progenitor cells into
ER-positive luminal cells. They also proposed that loss of
expression of the DNA repair gene (BRCA1) may result in
an accumulation of ER-negative stem cells with multiple
genetic defects. Incidentally, loss of BRCA1 is frequently
associated with ER-negative breast cancers [35]. The evi-
dence for altered gene expression possibly caused by
childhood body size helps to explain the general reduc-
tion in breast cancer risk overall. The apparent differen-
tial protection conferred to the ER-negative subtype
could possibly be driven by the same underlying mecha-
nism that operates through epigenetic modifications.
The strengths of our study include it being a popula-
tion-based study, its large sample size and detailed infor-
mation on many variables: anthropometric measures at
different time points throughout life, mammographic
density, reproductive and hormonal risk factors, and
tumour characteristics. To our knowledge, this is the first
study to consider the effects of somatotype at age seven
years on adult breast cancer with the consideration of
mammographic density, and also the first to examine its
effects on tumour characteristics other than ER status.
A limitation of our study is that risk factor data were
self-reported, and could thus be measured with error.
Although two studies have demonstrated the validity of
using the nine-level somatotype diagram for the long-
term recall of childhood body size via high correlations
with BMI at the same ages [8,36], it is noteworthy that in
those studies no woman recalled their figure as larger
than level seven in these studies, and that women with
large body size were more likely to misreport their child-
hood somatotypes than women who were lean. However,
any such measurement error is most likely to attenuate
any association between childhood body size and breast
cancer risk [37]. In addition, as the questionnaire study
was conducted post-diagnosis of breast cancer, recall bias
could have been introduced. Although the nine-level
somatotype measure has not been validated specifically
in a group of breast cancer cases, it is unlikely that child-
hood body size was differentially recalled by breast can-
cer cases and by controls.
Conclusions
Our findings may have important implications. The
effects of childhood body size on the different breast can-
cer subtypes are independent of other breast cancer risk
factors, such as mammographic density and estrogen
exposure. Given the strength of the associations, and the
ease of retrieval of information on childhood somato-
types retrospectively from pictures early in life, childhood
body size is potentially useful for building breast cancer
risk or prognosis prediction models. It appears counter-
intuitive that a large body size during childhood can
reduce breast cancer risk or alter one's prognosis, because
a large birth weight and a high adult BMI have been
shown to otherwise elevate breast cancer risk. There
remain unanswered questions on mechanisms driving
this protective effect. Because body size and related hor-
monal exposures are modifiable risk factors, women
might substantially decrease their risk of breast cancer, in
particular the more aggressive ER-negative disease, by
monitoring their nutrition and exogenous hormone
intake at different points in life.
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